[{"orgOrder":0,"company":"Axon Drugs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nature Aging Publishes Phase II Results for AADvac1, a First-in-Man Alzheimer's Tau Vaccine Developed by Axon Neuroscience","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Axon Drugs"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suven Life Sciences Announces Phase 3 Clinical Trial of SUVN-502 for Treatment of Agitation and Aggression in Alzheimer\u2019s Type Dementias","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Suven Life Sciences Limited"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"MediCane Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Suven Life Sciences Breathes New Life Into Drug Discovery Plans","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Suven Life Sciences Limited"},{"orgOrder":0,"company":"Sun Pharma Advanced Research Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SPARC Completes Enrolment in PROSEEK, Phase 2 Study of Vodobatinib in Early Parkinson\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Sun Pharma Advanced Research Company"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
As part of a collaboration between Dr. Reddy's and MediCane that started in 2021, MediCane will supply the medical cannabis products to Dr. Reddy's from its EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support.
K0706 (vodobatinib) is a potential first-in-class, highly selective and brain penetrating c-Abl inhibitor. It is being evaluated in patients with Parkinson’s disease, Dementia with Lewy Body and Chronic Myelogenous Leukemia.
SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.
SUVN-502 (Masupirdine), a lead clinical candidate having undergone phase 2 study on 564 patients for moderate Alzheimer’s disease without meeting primary end point.